The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer

Yoshiyuki Sugimoto, Maiko Hirota, Kazuhiro Yoshikawa, Makoto Sumitomo, Kogenta Nakamura, Ryuzo Ueda, Rinpei Niwa, Toshiyuki Suzawa, Motoo Yamasaki, Kenya Shitara, Takashi Kato, Kazuyasu Nakamura

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Prostate-specific membrane antigen (PSMA) is an attractive target for treatment of prostate cancer. Using the PSMA-recognizing mouse monoclonal antibody 2C9 obtained in our previous study, the biological activities of PSMA antibody were evaluated. Mouse-human chimeric IgG1 of 2C9 (KM2777) showed antibody-dependent cellular cytotoxicity activity against PSMA-expressing prostate cancer cells in the presence of human peripheral blood mononuclear cells (PBMCs). To increase lymphocyte-mediated cytotoxicity of KM2777, C-terminus interleukin-2 (IL-2)-fused KM2777 (KM2812) was constructed. KM2812 retained binding activity to PSMA and exhibited growth-stimulating activity equivalent to IL-2 on the IL-2-dependent T-cell line CTLL-2. Moreover, KM2812 exhibited enhanced cytotoxic activity against PSMA-expressing prostate cancer cells in the presence of PBMCs compared with KM2777. In a xenograft tumor model using PSMA-expressing prostate cancer cells, KM2812 exhibited marked antitumor activity, accompanied by complete regression of tumor in some of the KM2812-treated mice. These results suggest that KM2812 has a therapeutic potential for prostate cancer by stimulating lymphocyte-mediated antitumor cytotoxicity.

Original languageEnglish
Pages (from-to)89-97
Number of pages9
JournalAnticancer research
Volume34
Issue number1
Publication statusPublished - 01-01-2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer'. Together they form a unique fingerprint.

Cite this